Edgar Filing: NOVO NORDISK A S - Form 6-K

NOVO NORDISK A S Form 6-K August 26, 2008

> UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

> > -----

FORM 6-K

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

August 26, 2008

NOVO NORDISK A/S (Exact name of Registrant as specified in its charter)

NOVO ALLE DK-2880, BAGSVAERD DENMARK (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form $20\text{-}\mathrm{F}$ or Form $40\text{-}\mathrm{F}$

Form 20-F [X] Form 40-F []

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [] No [X]

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

TRANSACTION IN OWN SHARES

NOVO NORDISK A/S - SHARE REPURCHASE PROGRAMME

On 15 August 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

1

Edgar Filing: NOVO NORDISK A S - Form 6-K

Under the programme Novo Nordisk will repurchase B shares for an amount of up to DKK 1.7 billion in the period from 15 August 2008 to 19 December 2008.

Since the announcement as of 15 August 2008, the following transactions have been made under the programme:

| | | AVERAGE | TRANSACTION |
|---------------------------------|------------------|----------------|-------------|
| | NUMBER OF SHARES | PURCHASE PRICE | VALUE, DKK |
| 15 August 2008 | 50,000 | 310.5600 | 15,528,000 |
| 18 August 2008 | 50,000 | 310.1800 | 15,509,000 |
| 19 August 2008 | 60,000 | 299.9000 | 17,994,000 |
| 20 August 2008 | 50,000 | 298.3600 | 14,918,000 |
| 21 August 2008 | 50,000 | 295.1700 | 14,758,500 |
| 22 August 2008 | 50,000 | 292.7000 | 14,635,000 |
| ACCUMULATED UNDER THE PROGRAMME | 310,000 | | 93,342,500 |

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 51,070 B-shares in the period from 14 August 2008 to 21 August 2008. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 21,522,960 treasury shares, corresponding to 3.4% of the share capital. The total amount of shares in the company is 634,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,300 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:

Media:

Mette Kruse Danielsen Tel: (+45) 4442 3883 mkd@novonordisk.com Investors:

Mads Veggerby Lausten Tel: (+45) 4443 7919 mlau@novonordisk.com

Hans Rommer Tel: (+45) 4442 4765 hrmm@novonordisk.com

In North America: Sean Clements Tel: (+1) 609 514 8316 secl@novonordisk.com

Company Announcement no 53 / 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the

Edgar Filing: NOVO NORDISK A S - Form 6-K

undersigned, thereunto duly authorized.

Date: August 26, 2008

NOVO NORDISK A/S

Lars Rebien Sorensen, President and Chief Executive Officer